Search results
Showing 1601 to 1650 of 3765 results for treatment
Question What is the clinical and cost effectiveness, post-treatment and at longer-term follow‑up, of a brief psychosocial intervention...
This quality standard covers the safe and effective use of medicines. It covers people of all ages who are taking medicines, including those who are not getting the full benefit from their medicines. It describes high-quality care in priority areas for improvement.
View quality statements for QS120Show all sections
Sections for QS120
- Quality statements
- Quality statement 1: Shared decision-making
- Quality statement 2: Patient involvement in reporting medicines-related patient safety incidents
- Quality statement 3: Learning from medicines-related patient safety incidents
- Quality statement 4: Medicines reconciliation in acute settings
- Quality statement 5: Medicines reconciliation in primary care
- Quality statement 6: Structured medication review
- About this quality standard
This indicator covers tooth extractions due to decay for children admitted as inpatients to hospital, aged 10 years and under. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
autologous stem cell transplantation, plus consolidation and maintenance treatment in chemosensitive patients at first response or first...
precipitating event alone improve the hepatic encephalopathy without specific treatment? Any explanatory notes(if applicable) Why this...
Intrapartum care: existing medical conditions and obstetric complications (QS192)
This quality standard covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. It also covers women who have had no antenatal care. It describes high-quality care in priority areas for improvement. It does not cover the antenatal and postnatal care of pregnant women with mental health conditions, hypertension in pregnancy, diabetes in pregnancy or the organisation of care for pregnant women with complex social factors.
View quality statements for QS192Show all sections
Sections for QS192
- Quality statements
- Quality statement 1: Involving women in care planning
- Quality statement 2: Composition of the multidisciplinary team
- Quality statement 3: Heart disease – risk assessment
- Quality statement 4: Assessment and antibiotic treatment for suspected sepsis
- Quality statement 5: Women with no antenatal care
- Update information
- About this quality standard
Awaiting development Reference number: GID-TA10453 Expected publication date: TBC
NG191/3 Question What is the effectiveness and safety of a treatment dose with a low molecular weight heparin (LMWHs) compared with a...
UrgoStart for treating diabetic foot ulcers and leg ulcers (HTG502)
Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers.
aim to reduce time from initial presentation to referral, diagnosis and treatment? Any explanatory notes(if applicable) Why this is...
people with atrial fibrillation according to baseline risk factors and treatment? Any explanatory notes(if applicable) Source guidance
Cabotegravir for preventing HIV-1 in adults and young people (TA1106)
Evidence-based recommendations on cabotegravir (Apretude) for preventing HIV-1 in adults and young people.
Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (HTG729)
Evidence-based recommendations on digital technologies for assessing attention deficit hyperactivity disorder (ADHD).
NICE has developed a medtech innovation briefing (MIB) on eXroid for internal haemorrhoids .
Advanced breast cancer: diagnosis and management (Partial update)
In development Reference number: GID-NG10430 Expected publication date: TBC
controlled trials. Studies should describe clearly whether its use is for treatment or prevention. They should report details of patient...
Lipids disorders: FH assessment (29 years and under) (IND203)
This indicator covers the percentage of people aged 29 years and under, with a total cholesterol concentration greater than 7.5 mmol/l that are assessed against the Simon Broome or Dutch Lipid Clinic Network (DLCN) criteria. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM182
EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules (HTG611)
Evidence-based recommendations on EarlyCDT Lung for assessing the risk of lung cancer in solid lung nodules.
and (b) provision of adrenaline injectors, when compared with emergency treatment alone? Any explanatory notes(if applicable) Why this...
report long-term outcomes, in particular the need for subsequent surgical treatment. Any explanatory notes(if applicable) Current...
NICE has developed a medtech innovation briefing (MIB) on Aptiva for painful diabetic neuropathy .
Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.
NICE has developed a medtech innovation briefing (MIB) on AlignRT for intracranial stereotactic radiosurgery .
Current evidence on the safety and efficacy of radially emitting laser fibre treatment of an anal fistula is limited in quantity and...
adjunctive treatments. Outcome measures should include symptom relief and functional ability in the short term and the need for further...
Diabetes: blood pressure (without moderate or severe frailty) (IND249)
This indicator covers the percentage of patients with diabetes on the register, aged 79 years and under without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if measured in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM233
non-Chinese herbal medicines safe and effective as first-line therapy in the treatment of [Irritable bowel syndrome] (IBS), and which is...
MMprofiler for prognostic risk classification in multiple myeloma (MIB270)
NICE has developed a medtech innovation briefing (MIB) on MMprofiler for prognostic risk classification in multiple myeloma .
Evidence-based recommendations on lead-I electrocardiogram (ECG) devices (imPulse, Kardia Mobile, MyDiagnostick and Zenicor-ECG) for detecting symptomatic atrial fibrillation using single time point testing in primary care.
information and support are needed by family members or carers of people having treatment with an opioid, benzodiazepine, Z‑drug,...
Awaiting development Reference number: GID-TA10605 Expected publication date: TBC
Awaiting development Reference number: GID-TA10657 Expected publication date: TBC
people diagnosed with early AMD, indeterminate AMD or late AMD (dry) lead to earlier treatment and better long-term outcomes? Any...
This guideline covers care before, during and after a planned knee, hip or shoulder replacement. It includes recommendations to ensure that people are given full information about their options for surgery, including anaesthesia. It offers advice for healthcare professionals on surgical procedures and ensuring safety during operations. It also offers guidance on providing support and rehabilitation before and after surgery.
risk of hepatitis B and C infection to take up the offer of testing and treatment? Any explanatory notes(if applicable) None. Source...
Awaiting development Reference number: GID-TA11216 Expected publication date: TBC
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (HTG719)
Evidence-based recommendations on tumour profiling tests (EndoPredict, ICH4+C, MammaPrint, Oncotype DX and Prosigna) to guide adjuvant chemotherapy decisions in early breast cancer.
the safety of unilateral MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor, which could include...
Osteoporosis: bone sparing agents (75 years and over) (IND92)
This indicator covers the percentage of patients aged 75 or over with a fragility fracture on or after 1 April 2012, who are currently treated with an appropriate bone-sparing agent. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM31
This indicator covers the percentage of patients aged 50 or over and who have not attained the age of 75, with a record of a fragility fracture on or after 1 April 2012, in whom osteoporosis is confirmed on DXA scan, who are currently treated with an appropriate bone-sparing agent. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM30
Acoustic CR Neuromodulation for adults with chronic subjective tonal tinnitus (MIB5)
NICE has developed a Medtech Innovation Briefing (MIB) on the Acoustic CR Neuromodulation system
NICE has developed a Medtech Innovation Briefing (MIB) on the Oncentra Prostate v4.x ultrasound-guided real-time HDR brachytherapy in men with localised
and cost effectiveness of cannabis-based medicinal products as an add-on treatment for adults with chemotherapy-induced nausea and...
Digital technologies for managing non-specific low back pain: early value assessment (HTG712)
Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over.
NICE has developed a medtech innovation briefing (MIB) on AlignRT in breast cancer radiotherapy .
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid opportunistic detection of vertebral fragility fractures.
PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis (MIB313)
NICE has developed a medtech innovation briefing (MIB) on PredictSURE IBD for inflammatory bowel disease prognosis: ulcerative colitis .
luteal phase support treatments in IVF:- Further research is needed to assess the efficacy of adjuvant luteal phase support...